Advocacy intelligence hub — real-time data for patient organizations
National Cancer Institute (NCI) — PHASE2
Nulojix: FDA approved
Prophylaxis of organ rejection in adult patients receiving kidney transplants
Proleukin: FDA approved
Treatment of adults (>18 years old) with metastatic renal cell carcinoma.
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Patient Assistance Programs2
Proleukin
(Aldesleukin)Orphan drugChiron Corporation
Lymphocyte Growth Factor [EPC]
12.1 Mechanism of Action Aldesleukin is an interleukin-2 lymphocyte growth factor. The antitumor activity of aldesleukin has not been fully characteri...
Browse all MiT family translocation renal cell carcinoma news →
Wenxin Xu, MD, M.D
Dana-Farber Cancer Institute
📍 BOSTON, MA
Ramaprasad Srinivasan, M.D., M.D
National Cancer Institute (NCI)
📍 BETHESDA, MD
James I Geller
Children's Oncology Group
📍 Birmingham, Alabama
Camila MV Moniz, Doctor
Oncologist
📍 SAN ANTONIO, TX
Bradley McGregor, MD, MD
Dana-Farber Cancer Institute
📍 BOSTON, MA
Martin Voss, MD, MD
Memorial Sloan Kettering Cancer Center
📍 EAU CLAIRE, WI
View all MiT family translocation renal cell carcinoma specialists →